FDA approves Ionis' RNA-based treatment for rare Alexander disease

Ionis Pharmaceuticals has received FDA approval for zilganersen, an RNA-based therapy designed to treat Alexander disease, a rare neurodegenerative condition affecting children. This marks the company's first wholly owned neurology product to reach the market. The approval expands Ionis' commercial portfolio beyond its partnered drugs.

The regulatory clearance of zilganersen provides a new therapeutic option for Alexander disease, a rare neurodegenerative disorder that primarily impacts pediatric patients. This approval signifies a milestone for the developer, as it represents the first neurology medication wholly owned by the company to secure market authorization.

With this decision, the company's commercial lineup now extends beyond its previously partnered treatments. The RNA-based mechanism of the drug highlights a growing focus on nucleic acid therapeutics for challenging neurological conditions.